APSHO Cancer Therapy Prescribing Course
-
Register
- Non-member - $625
- Member - $500
The Cancer Therapy Prescribing Course is a comprehensive, CE-accredited course for nurse practitioners, PAs, and pharmacists benchmarking the education that advanced practitioners need to safely prescribe cancer therapy. Topics include chemotherapy, targeted therapy, and immunotherapy prescribing best practices.
Advanced Search This List
-
Contains 10 Component(s)
To see the Learning Objectives and Outline for this section click the "View" button below.
Outline:
- Introduction and Background
- Risk-Inducing Factors for Medical Therapy Errors
- Response and Toxicity Assessment
- Guidelines and Standards for Safe Prescribing and Administration of Cancer Chemotherapy
After completing this educational activity, participants should be able to:
- Identify patient, pharmacologic, and care delivery factors that make cancer therapy a high-risk process
- Describe unique timing intervals for administration of cancer therapies
- Explain standard disease-specific processes to monitor cancer therapy response
- Describe standard organizational policies and practices that ensure safe cancer therapy prescribing and administration
Lynn Adams
DNP, ANP-BC, AOCNP®
Memorial Sloan Kettering Cancer Center
Dr. Adams is an APP manager at Memorial Sloan Kettering Cancer Center Long Island Regional Network sites. A former president of the Oncology Nursing Society (Suffolk County chapter), Lynn is a past winner of the Samuel and May Rudin Award for Excellence in Advanced Nursing Practice at Memorial Sloan Kettering Cancer Center. She has authored or co-authored 9 articles and presented more than 40 times since starting her career as a clinical nurse in 1982.
Dr. Adams has no relevant financial relationships to disclose.
-
Contains 8 Component(s)
To see the Learning Objectives and Outline for this section click the "View" button below.
Outline:
- Terminology and Concepts
- Classes of Chemotherapy Agents
- Cell Cycle Non-Specific Agents
- Cell Cycle-Specific Agents
- Clinical Pearls and Case Study
After completing this educational activity, participants should be able to:
- List the various classes of therapeutic agents
- Describe the unique characteristics of each chemotherapy class, including dose limitations, common toxicities, and black box warnings
Joseph A. Kalis
PharmD, BCOP
UCHealth Hematology/Oncology, Colorado Springs, Colorado
Dr. Joseph A. Kalis is an Ambulatory Oncology Clinical Specialist with UCHealth Memorial Hospital in Colorado Springs, Colorado, where he is part of a large community oncology practice. His passion is helping patients become fully invested and engaged in their cancer care. The role of "pharmacist-as-educator" is central to his practice. Dr. Kalis believes that education is most effective when approached with a philosophy of collegiality.
Dr. Joseph A. Kalis, PharmD, BCOP, has the following relevant financial relationships to disclose:
- Speakers' Bureau: GlaxoSmithKline, Oncopeptides
-
Contains 12 Component(s)
To see the Learning Objectives and Outline for this section click the "View" button below.
Outline
- Introduction to Targeted Therapy
- Definitions and History
- Monoclonal Antibodies
- Definition, Discovery
- Mechanism of Action
- Drug Classes
- Antibody-Drug Conjugates
- Small-Molecule Agents
- Definition and History
- Tyrosine Kinase Inhibitors
- Other Small Molecules
- General Approach for APs
- Understanding Targeted Therapies
- Obtaining Consent
- Considerations for Special Populations
After completing this educational activity, participants should be able to:
- Describe the mechanisms of action for common targeted therapies, including monoclonal antibodies and small-molecule targeted agents
- Describe the unique characteristics of common classes of targeted therapies
- Develop an approach for understanding new agents in this rapidly growing field
Jennifer Jacky
MSN, ARNP, AOCNP®
Fred Hutchinson Cancer Center, University of Washington
Ms. Jacky is a is a board-certified oncology nurse practitioner specializing in thoracic and head and neck malignancies. She works as an APP lead at the Fred Hutchinson Cancer Center. Her interests include clinical trials, optimizing symptom control, and primary palliative care.
Jennifer Jacky has no relevant financial relationships to disclose.
Gabrielle Zecha
PA-C, MHA
Fred Hutchinson Cancer Center, University of Washington
Ms. Zecha is a board-certified PA who specializes in the treatment of blood disorders and is the director for the more than 200 advanced practice providers in oncology and stem cell transplant at the Fred Hutchinson Cancer Center and the University of Washington. She has spent her career in oncology in a diverse array of settings, including stem cell transplant, general oncology, and hematologic malignancies.
Gabrielle Zecha has no relevant financial relationships to disclose.
-
Contains 8 Component(s)
To see the Learning Objectives and Outline for this section click the "View" button below.
Outline:
- Risk Evaluation and Mitigation Strategies (REMS)
- Immunomodulatory Drugs (IMiDs)
- Proteasome Inhibitors (PIs)
- Lymphocyte Activation Gene 3 (LAG-3)
- Additional Antineoplastic Agentss
After completing this educational activity, participants should be able to:
- Describe the REMS program and how it applies to select cancer therapies
- Identify the unique prescribing considerations of immunomodulary drugs, proteosome inhibitors, arsenic trioxide, and tretinoin
- Recognize key toxicities and black box warnings of the cancer therapies included in this module
Kirollos Hanna
PharmD, BCPS, BCOP
M Health Fairview and Mayo Clinic College of Medicine
Dr. Hanna is board certified in Oncology Pharmacy and Pharmacotherapy. He is an Assistant Professor of Pharmacy at the Mayo Clinic College of Medicine and the Oncology Pharmacy Manager at M Health Fairview, Maple Grove, Minnesota. Dr. Hanna serves as an Associate Editor for JADPRO (Journal of the Advanced Practitioner in Oncology). His research interests focus on B-cell malignancies and genitourinary cancers, and he has published over a dozen peer-reviewed manuscripts in various journals. Dr. Hanna serves on the Executive Council of the National Community Oncology Dispensing Association (NCODA). He has been awarded the 2018 "40 Under 40 in Cancer" by The Lynx Group, Upstream Partners, Swim Across America, and NCODA; the "Next Generation 2019 Specialty Pharmacist" by PharmacyTimes and Parata Systems; and the 2020 " New Practitioner Award" by HOPA.
Kirollos Hanna has the following relevant financial relationships to disclose:
- Speakers bureau: AbbVie, Astellas, Beigene, Bristol Myers Squibb, Exelixis, PCYC, Seagen
- Consultant: AbbVie, Seagen
-
Contains 10 Component(s)
To see the Learning Objectives and Outline for this section click the "View" button below.
Outline:
- Checkpoint Inhibitors
- Anti-Programmed Cell Death Protein 1 (PD-1)
- Anti-Programmed Death-Ligand 1 (PD-L1)
- Anti-Cytotoxic T-Lymphocyte Associated Protein 4 (CTLA-4)
- Lymphocyte Activation Gene 3 (LAG-3)
- General Immune Checkpoint Inhibitor Toxicities
- Immune-Related Adverse Events (irAEs)
- Viral Therapy
- Interferons
- Interleukins
After completing this educational activity, participants should be able to:
- List the various classes of therapeutic agents
- Describe the unique characteristics of each class of immunotherapies including:
- Dose limitations
- Common toxicities
- Black box warnings
Michela Altergott
PharmD
St. Luke’s Cancer Institute Boise
Dr. Altergott is the lead oncology pharmacist at St. Luke’s Cancer Institute in Boise, Idaho, as well as a lecturer at Idaho State University. She spearheaded a resident project to create a new clinical pharmacist position in the medical oncology clinic to work directly with the oncologists, advanced practice providers, and patients. She co-published a research article in Oncology Issues in 2021 and has participated in research presented at several conferences, including the 2021 Mountain States Residency Conference and 2021 Hematology Oncology Pharmacy Association Spring Conference. She has served on St. Luke’s Medication Safety Committee since 2016 and the IV Room Task Force Committee since 2019.
Dr. Altergott has no relevant financial relationships to disclose.
-
Contains 10 Component(s)
To see the Learning Objectives and Outline for this section click the "View" button below.
Outline:
- Overview of Cellular Therapy
- Identification of the Patient Who Would Benefit From Cellular Therapy
- Toxicities and Management
- Patient Education
After completing this educational activity, participants should be able to:
- Describe basic concepts of cellular therapy
- Identify patients who might benefit from cellular therapy
- Recognize common toxicities of therapy and corresponding management recommendations
Christine Cambareri
PharmD, BCOP, CSP
Abramson Cancer Center
Dr. Cambareri is an oncology clinical pharmacy specialist at the Abramson Cancer Center at the Hospital of the University of Pennsylvania. In her various roles at Penn, she has provided education and counseling on oral and intravenous chemotherapies, side effect management, and herbal therapy consults, and served as a drug information resource for her patients and providers. Before working at Penn, she completed two years of post-graduate pharmacy training, training at Christiana Care in Newark, Delaware, for a Pharmacotherapy Residency and at Yale New Haven Health System in New Haven, Connecticut, for a Hematology/Oncology Pharmacy Residency. Christine received her Bachelors of Science degree in Biomedical Engineering from Rensselaer Polytechnic Institute in Troy, New York, and her Doctor of Pharmacy Degree from Albany College of Pharmacy and Health Sciences in Colchester, Vermont.
Dr. Cambareri has no relevant financial relationships to disclose.
Meredith Beaton
MSN, AG-ACNP, RN
Division of Hematology at the University of Colorado, Anschutz Medical Campus
Ms Beaton is an Assistant Professor in the Division of Hematology at the University of Colorado, Anschutz Medical Campus, and is the APP Clinical Director of the Blood Disorders Center at the University of Colorado Hospital. Since becoming the APP Clinical Director, she has worked closely with the APP team and other leadership within the Division and UCH to expand the role of APPs to encourage promotion and involvement in QI and research projects beyond clinical work. She also works with the Department of Medicine’s Office of Professional Excellence to promote both individual and professional growth for all team members within the Division of Hematology. Additionally, she promotes education and mentorship within the Division through her work coordinating the onboarding and education of new hire APPs, students, residents, and fellows with the inpatient BMT team as well as within the School of Nursing through guest lectures and precepting NP students. In her work as an APP, she draws heavily on her prior careers as a middle school teacher, computer scientist, and researcher of youth, media, and technology to inform how she approaches problems within the team and collaborates with others to create new opportunities for growth and development.
Ms. Beaton has no relevant financial relationships to disclose.
-
Contains 10 Component(s)
To see the Learning Objectives and Outline for this section click the "View" button below.
Outline:
- Regulatory Requirements for Prescribing Antineoplastic Therapy
- Investigational Therapy Prescribing
- Basic Principles of Safety for Prescribing Antineoplastic Agents
- Assessment Prior to Prescribing a New Regimen
- Assessment Prior to Subsequent Cycles or Doses
After completing this educational activity, participants should be able to:
- Describe national, state, and institutional regulatory guidelines for prescribing antineoplastic agents
- Identify available resources to guide safe prescribing practices for standard therapies or investigational agents
- Apply key elements of a comprehensive process for patient assessment prior to prescribing antineoplastic therapies that is tailored to the individual patient
- Analyze individual practices for gaps in workflow or resources to facilitate practice improvement for expanded role of the AP in prescribing antineoplastic agents
Sandra Kurtin
PhD, ANP-BC, AOCN®, FAPO
The University of Arizona Cancer Center
Sandra Kurtin, PhD, ANP-C, AOCN®, FAPO, is a Nurse Practitioner, Clinical Assistant Professor of Medicine, and Adjunct Clinical Assistant Professor of Nursing at the University of Arizona Cancer Center in Tucson. She has 38 years of oncology experience and maintains a busy clinical practice, with expertise in hematologic malignancies, clinical trials, symptom management, supportive care, caregiver support, and health informatics. Dr. Kurtin is a founding board member of APSHO and an active member of the American Society of Hematology, the American Society of Clinical Oncology, and the Oncology Nursing Society. Dr. Kurtin serves on a number of patient advocacy boards, professional working groups, and editorial boards for peer-reviewed publications relevant to oncology and supportive care. She is widely published in peer-reviewed journals and lectures nationally and internationally.
Dr. Kurtin has the following relevant financial relationships to disclose:- Consultant: AstraZeneca, Bristol Myers Squibb, Epizyme, Incyte, Pharmacyclics, Takeda
-
Contains 10 Component(s)
To see the Learning Objectives and Outline for this section click the "View" button below.
Outline:
- Types of Dosing
- Routes of Administration
- Renal and Hepatic Dosing
- Drug Interactions
- Dose Adjustments
After completing this educational activity, participants should be able to:
- List the most common dosing units and administration routes for cancer therapy
- Understand dosing calculations in cancer therapies
- Identify instances when dose reduction, dose delay, or treatment discontinuation are appropriate
- Describe common drug interaction pathways and management strategies
Donald C. Moore
PharmD, BCPS, BCOP, DPLA, FCCP
Levine Cancer Institute, Atrium Health
Dr. Moore is the clinical oncology pharmacy manager at Levine Cancer Institute, practicing inpatient and outpatient hematology/oncology, with a particular interest in malignant and benign hematology and in treating patients on early phase clinical trials with investigational agents. He has authored original research articles, review articles, and case reports in numerous journals. He was awarded the 2020 “40 Under 40 in Cancer” Award by the National Community Oncology Dispensing Association, The Lynx Group, and the Association of Value-Based Cancer Care.
Dr. Moore has the following relevant financial relationships to disclose:- Advisory Boards: AstraZeneca, Janssen, Oncopeptides, Pfizer
-
Contains 8 Component(s)
To see the Learning Objectives and Outline for this section click the "View" button below.
Outline:
- Electrolyte Management
- Tumor Lysis Syndrome
- Hydration Support
- Nutrition Management
- Anorexia/Cachexia
After completing this educational activity, participants should be able to:
- Describe appropriate management strategies for the prevention and treatment of electrolyte disorders
- Assess risk for tumor lysis syndrome and prescribe appropriate prophylaxis
- Assess nutrition status and manage cachexia and anorexia
Alison Morris
DNP, FNP-BC
Stanford Health Care
Alison Morris is a Hematology/Oncology Nurse Practitioner at Stanford Healthcare (SHC). Caring for cancer patients has been her passion since she was a nursing student. Alison began her career at UCLA in inpatient medical oncology in 2007 and later moved to Northern California. She has been working at Stanford Healthcare for the past 14 years. Alison worked as an inpatient Hematology/Oncology nurse, then as a Nurse Practitioner in inpatient Hematology/Oncology. She transitioned to outpatient Hematology/Oncology at Stanford Cancer Center- South Bay (CCSB), first as an Infusion Treatment Area APP and then transitioned to a mostly independent clinic practice caring for a spectrum of oncology and hematology patients. She is also the Lead APP at CCSB. She completed her Master’s in Nursing in 2013, and earned her Doctor of Nursing Practice (DNP) in 2015.
Dr. Morris has no relevant financial relationships to disclose.
-
Contains 10 Component(s)
To see the Learning Objectives and Outline for this section click the "View" button below.
Outline:
- Immune-related adverse events
- Radiation toxicities
- Endocrine therapy
- Bone health and management
After completing this educational activity, participants should be able to:
- Describe appropriate management strategies for prevention and treatment of immune-related adverse events
- Identify and manage adverse events related to endocrine therapy
- Describe risk factors for bone toxicity and prescribe preventative and management strategies
Alison Morris
DNP, FNP-BC
Stanford Health Care
Alison Morris is a Hematology/Oncology Nurse Practitioner at Stanford Healthcare (SHC). Caring for cancer patients has been her passion since she was a nursing student. Alison began her career at UCLA in inpatient medical oncology in 2007 and later moved to Northern California. She has been working at Stanford Healthcare for the past 14 years. Alison worked as an inpatient Hematology/Oncology nurse, then as a Nurse Practitioner in inpatient Hematology/Oncology. She transitioned to outpatient Hematology/Oncology at Stanford Cancer Center- South Bay (CCSB), first as an Infusion Treatment Area APP and then transitioned to a mostly independent clinic practice caring for a spectrum of oncology and hematology patients. She is also the Lead APP at CCSB. She completed her Master’s in Nursing in 2013, and earned her Doctor of Nursing Practice (DNP) in 2015.
Dr. Morris has no relevant financial relationships to disclose.
This course was developed by the Advanced Practitioner Society for Hematology and Oncology (APSHO). Any recommendations contained in this course reflect APSHO's or Harborside's judgement regarding the state of general knowledge and practice in the field as of the date of publication. The recommendations may not be appropriate for use in all circumstances. APSHO and Harborside neither represent nor guarantee that the practices described herein will, if followed, ensure safe and effective patient care. Every healthcare provider should make their own determination regarding specific safe and appropriate patient care practices, including drug dosages and indications, considering patient specific characteristics, institutional policies and procedures, personnel, and equipment. The provider should always consult the most recent prescribing/product information. Though APSHO and the content creators have applied a rigorous review process to produce an error-free module, inadvertent mistakes can occur during the writing/editing/proofreading process. Information is not guaranteed to be accurate, complete, or current. APSHO, its editors, authors and reviewers cannot be held responsible for any liability incurred as a consequence for the application of any of the contents of this course contents. Figures and tables are used as examples and are not meant to be all-inclusive, nor do they represent endorsement of any particular therapy or institution. Websites mentioned are provided for information only and the website hosts are responsible for their own content and availability.
-
Contains 10 Component(s)
To see the Learning Objectives and Outline for this section click the "View" button below.
Outline:
- Introduction and Background
- Risk-Inducing Factors for Medical Therapy Errors
- Response and Toxicity Assessment
- Guidelines and Standards for Safe Prescribing and Administration of Cancer Chemotherapy
After completing this educational activity, participants should be able to:
- Identify patient, pharmacologic, and care delivery factors that make cancer therapy a high-risk process
- Describe unique timing intervals for administration of cancer therapies
- Explain standard disease-specific processes to monitor cancer therapy response
- Describe standard organizational policies and practices that ensure safe cancer therapy prescribing and administration
Lynn Adams
DNP, ANP-BC, AOCNP®
Memorial Sloan Kettering Cancer Center
Dr. Adams is an APP manager at Memorial Sloan Kettering Cancer Center Long Island Regional Network sites. A former president of the Oncology Nursing Society (Suffolk County chapter), Lynn is a past winner of the Samuel and May Rudin Award for Excellence in Advanced Nursing Practice at Memorial Sloan Kettering Cancer Center. She has authored or co-authored 9 articles and presented more than 40 times since starting her career as a clinical nurse in 1982.
Dr. Adams has no relevant financial relationships to disclose.
-
Contains 8 Component(s)
To see the Learning Objectives and Outline for this section click the "View" button below.
Outline:
- Terminology and Concepts
- Classes of Chemotherapy Agents
- Cell Cycle Non-Specific Agents
- Cell Cycle-Specific Agents
- Clinical Pearls and Case Study
After completing this educational activity, participants should be able to:
- List the various classes of therapeutic agents
- Describe the unique characteristics of each chemotherapy class, including dose limitations, common toxicities, and black box warnings
Joseph A. Kalis
PharmD, BCOP
UCHealth Hematology/Oncology, Colorado Springs, Colorado
Dr. Joseph A. Kalis is an Ambulatory Oncology Clinical Specialist with UCHealth Memorial Hospital in Colorado Springs, Colorado, where he is part of a large community oncology practice. His passion is helping patients become fully invested and engaged in their cancer care. The role of "pharmacist-as-educator" is central to his practice. Dr. Kalis believes that education is most effective when approached with a philosophy of collegiality.
Dr. Joseph A. Kalis, PharmD, BCOP, has the following relevant financial relationships to disclose:
- Speakers' Bureau: GlaxoSmithKline, Oncopeptides
-
Contains 12 Component(s)
To see the Learning Objectives and Outline for this section click the "View" button below.
Outline
- Introduction to Targeted Therapy
- Definitions and History
- Monoclonal Antibodies
- Definition, Discovery
- Mechanism of Action
- Drug Classes
- Antibody-Drug Conjugates
- Small-Molecule Agents
- Definition and History
- Tyrosine Kinase Inhibitors
- Other Small Molecules
- General Approach for APs
- Understanding Targeted Therapies
- Obtaining Consent
- Considerations for Special Populations
After completing this educational activity, participants should be able to:
- Describe the mechanisms of action for common targeted therapies, including monoclonal antibodies and small-molecule targeted agents
- Describe the unique characteristics of common classes of targeted therapies
- Develop an approach for understanding new agents in this rapidly growing field
Jennifer Jacky
MSN, ARNP, AOCNP®
Fred Hutchinson Cancer Center, University of Washington
Ms. Jacky is a is a board-certified oncology nurse practitioner specializing in thoracic and head and neck malignancies. She works as an APP lead at the Fred Hutchinson Cancer Center. Her interests include clinical trials, optimizing symptom control, and primary palliative care.
Jennifer Jacky has no relevant financial relationships to disclose.
Gabrielle Zecha
PA-C, MHA
Fred Hutchinson Cancer Center, University of Washington
Ms. Zecha is a board-certified PA who specializes in the treatment of blood disorders and is the director for the more than 200 advanced practice providers in oncology and stem cell transplant at the Fred Hutchinson Cancer Center and the University of Washington. She has spent her career in oncology in a diverse array of settings, including stem cell transplant, general oncology, and hematologic malignancies.
Gabrielle Zecha has no relevant financial relationships to disclose.
- Introduction to Targeted Therapy
-
Contains 8 Component(s)
To see the Learning Objectives and Outline for this section click the "View" button below.
Outline:
- Risk Evaluation and Mitigation Strategies (REMS)
- Immunomodulatory Drugs (IMiDs)
- Proteasome Inhibitors (PIs)
- Lymphocyte Activation Gene 3 (LAG-3)
- Additional Antineoplastic Agentss
After completing this educational activity, participants should be able to:
- Describe the REMS program and how it applies to select cancer therapies
- Identify the unique prescribing considerations of immunomodulary drugs, proteosome inhibitors, arsenic trioxide, and tretinoin
- Recognize key toxicities and black box warnings of the cancer therapies included in this module
Kirollos Hanna
PharmD, BCPS, BCOP
M Health Fairview and Mayo Clinic College of Medicine
Dr. Hanna is board certified in Oncology Pharmacy and Pharmacotherapy. He is an Assistant Professor of Pharmacy at the Mayo Clinic College of Medicine and the Oncology Pharmacy Manager at M Health Fairview, Maple Grove, Minnesota. Dr. Hanna serves as an Associate Editor for JADPRO (Journal of the Advanced Practitioner in Oncology). His research interests focus on B-cell malignancies and genitourinary cancers, and he has published over a dozen peer-reviewed manuscripts in various journals. Dr. Hanna serves on the Executive Council of the National Community Oncology Dispensing Association (NCODA). He has been awarded the 2018 "40 Under 40 in Cancer" by The Lynx Group, Upstream Partners, Swim Across America, and NCODA; the "Next Generation 2019 Specialty Pharmacist" by PharmacyTimes and Parata Systems; and the 2020 " New Practitioner Award" by HOPA.
Kirollos Hanna has the following relevant financial relationships to disclose:
- Speakers bureau: AbbVie, Astellas, Beigene, Bristol Myers Squibb, Exelixis, PCYC, Seagen
- Consultant: AbbVie, Seagen
-
Contains 10 Component(s)
To see the Learning Objectives and Outline for this section click the "View" button below.
Outline:
- Checkpoint Inhibitors
- Anti-Programmed Cell Death Protein 1 (PD-1)
- Anti-Programmed Death-Ligand 1 (PD-L1)
- Anti-Cytotoxic T-Lymphocyte Associated Protein 4 (CTLA-4)
- Lymphocyte Activation Gene 3 (LAG-3)
- General Immune Checkpoint Inhibitor Toxicities
- Immune-Related Adverse Events (irAEs)
- Viral Therapy
- Interferons
- Interleukins
After completing this educational activity, participants should be able to:
- List the various classes of therapeutic agents
- Describe the unique characteristics of each class of immunotherapies including:
- Dose limitations
- Common toxicities
- Black box warnings
Michela Altergott
PharmD
St. Luke’s Cancer Institute Boise
Dr. Altergott is the lead oncology pharmacist at St. Luke’s Cancer Institute in Boise, Idaho, as well as a lecturer at Idaho State University. She spearheaded a resident project to create a new clinical pharmacist position in the medical oncology clinic to work directly with the oncologists, advanced practice providers, and patients. She co-published a research article in Oncology Issues in 2021 and has participated in research presented at several conferences, including the 2021 Mountain States Residency Conference and 2021 Hematology Oncology Pharmacy Association Spring Conference. She has served on St. Luke’s Medication Safety Committee since 2016 and the IV Room Task Force Committee since 2019.Dr. Altergott has no relevant financial relationships to disclose. -
Contains 10 Component(s)
To see the Learning Objectives and Outline for this section click the "View" button below.
Outline:
- Overview of Cellular Therapy
- Identification of the Patient Who Would Benefit From Cellular Therapy
- Toxicities and Management
- Patient Education
After completing this educational activity, participants should be able to:
- Describe basic concepts of cellular therapy
- Identify patients who might benefit from cellular therapy
- Recognize common toxicities of therapy and corresponding management recommendations
Christine Cambareri
PharmD, BCOP, CSP
Abramson Cancer Center
Dr. Cambareri is an oncology clinical pharmacy specialist at the Abramson Cancer Center at the Hospital of the University of Pennsylvania. In her various roles at Penn, she has provided education and counseling on oral and intravenous chemotherapies, side effect management, and herbal therapy consults, and served as a drug information resource for her patients and providers. Before working at Penn, she completed two years of post-graduate pharmacy training, training at Christiana Care in Newark, Delaware, for a Pharmacotherapy Residency and at Yale New Haven Health System in New Haven, Connecticut, for a Hematology/Oncology Pharmacy Residency. Christine received her Bachelors of Science degree in Biomedical Engineering from Rensselaer Polytechnic Institute in Troy, New York, and her Doctor of Pharmacy Degree from Albany College of Pharmacy and Health Sciences in Colchester, Vermont.
Dr. Cambareri has no relevant financial relationships to disclose.
Meredith Beaton
MSN, AG-ACNP, RN
Division of Hematology at the University of Colorado, Anschutz Medical Campus
Ms Beaton is an Assistant Professor in the Division of Hematology at the University of Colorado, Anschutz Medical Campus, and is the APP Clinical Director of the Blood Disorders Center at the University of Colorado Hospital. Since becoming the APP Clinical Director, she has worked closely with the APP team and other leadership within the Division and UCH to expand the role of APPs to encourage promotion and involvement in QI and research projects beyond clinical work. She also works with the Department of Medicine’s Office of Professional Excellence to promote both individual and professional growth for all team members within the Division of Hematology. Additionally, she promotes education and mentorship within the Division through her work coordinating the onboarding and education of new hire APPs, students, residents, and fellows with the inpatient BMT team as well as within the School of Nursing through guest lectures and precepting NP students. In her work as an APP, she draws heavily on her prior careers as a middle school teacher, computer scientist, and researcher of youth, media, and technology to inform how she approaches problems within the team and collaborates with others to create new opportunities for growth and development.
Ms. Beaton has no relevant financial relationships to disclose.
-
Contains 10 Component(s)
To see the Learning Objectives and Outline for this section click the "View" button below.
Outline:
- Regulatory Requirements for Prescribing Antineoplastic Therapy
- Investigational Therapy Prescribing
- Basic Principles of Safety for Prescribing Antineoplastic Agents
- Assessment Prior to Prescribing a New Regimen
- Assessment Prior to Subsequent Cycles or Doses
After completing this educational activity, participants should be able to:
- Describe national, state, and institutional regulatory guidelines for prescribing antineoplastic agents
- Identify available resources to guide safe prescribing practices for standard therapies or investigational agents
- Apply key elements of a comprehensive process for patient assessment prior to prescribing antineoplastic therapies that is tailored to the individual patient
- Analyze individual practices for gaps in workflow or resources to facilitate practice improvement for expanded role of the AP in prescribing antineoplastic agents
Sandra Kurtin
PhD, ANP-BC, AOCN®, FAPO
The University of Arizona Cancer Center
Sandra Kurtin, PhD, ANP-C, AOCN®, FAPO, is a Nurse Practitioner, Clinical Assistant Professor of Medicine, and Adjunct Clinical Assistant Professor of Nursing at the University of Arizona Cancer Center in Tucson. She has 38 years of oncology experience and maintains a busy clinical practice, with expertise in hematologic malignancies, clinical trials, symptom management, supportive care, caregiver support, and health informatics. Dr. Kurtin is a founding board member of APSHO and an active member of the American Society of Hematology, the American Society of Clinical Oncology, and the Oncology Nursing Society. Dr. Kurtin serves on a number of patient advocacy boards, professional working groups, and editorial boards for peer-reviewed publications relevant to oncology and supportive care. She is widely published in peer-reviewed journals and lectures nationally and internationally.Dr. Kurtin has the following relevant financial relationships to disclose:- Consultant: AstraZeneca, Bristol Myers Squibb, Epizyme, Incyte, Pharmacyclics, Takeda
-
Contains 10 Component(s)
To see the Learning Objectives and Outline for this section click the "View" button below.
Outline:
- Types of Dosing
- Routes of Administration
- Renal and Hepatic Dosing
- Drug Interactions
- Dose Adjustments
After completing this educational activity, participants should be able to:
- List the most common dosing units and administration routes for cancer therapy
- Understand dosing calculations in cancer therapies
- Identify instances when dose reduction, dose delay, or treatment discontinuation are appropriate
- Describe common drug interaction pathways and management strategies
Donald C. Moore
PharmD, BCPS, BCOP, DPLA, FCCP
Levine Cancer Institute, Atrium Health
Dr. Moore is the clinical oncology pharmacy manager at Levine Cancer Institute, practicing inpatient and outpatient hematology/oncology, with a particular interest in malignant and benign hematology and in treating patients on early phase clinical trials with investigational agents. He has authored original research articles, review articles, and case reports in numerous journals. He was awarded the 2020 “40 Under 40 in Cancer” Award by the National Community Oncology Dispensing Association, The Lynx Group, and the Association of Value-Based Cancer Care.Dr. Moore has the following relevant financial relationships to disclose:- Advisory Boards: AstraZeneca, Janssen, Oncopeptides, Pfizer
-
Contains 8 Component(s)
To see the Learning Objectives and Outline for this section click the "View" button below.
Outline:
- Electrolyte Management
- Tumor Lysis Syndrome
- Hydration Support
- Nutrition Management
- Anorexia/Cachexia
After completing this educational activity, participants should be able to:
- Describe appropriate management strategies for the prevention and treatment of electrolyte disorders
- Assess risk for tumor lysis syndrome and prescribe appropriate prophylaxis
- Assess nutrition status and manage cachexia and anorexia
Alison Morris
DNP, FNP-BC
Stanford Health Care
Alison Morris is a Hematology/Oncology Nurse Practitioner at Stanford Healthcare (SHC). Caring for cancer patients has been her passion since she was a nursing student. Alison began her career at UCLA in inpatient medical oncology in 2007 and later moved to Northern California. She has been working at Stanford Healthcare for the past 14 years. Alison worked as an inpatient Hematology/Oncology nurse, then as a Nurse Practitioner in inpatient Hematology/Oncology. She transitioned to outpatient Hematology/Oncology at Stanford Cancer Center- South Bay (CCSB), first as an Infusion Treatment Area APP and then transitioned to a mostly independent clinic practice caring for a spectrum of oncology and hematology patients. She is also the Lead APP at CCSB. She completed her Master’s in Nursing in 2013, and earned her Doctor of Nursing Practice (DNP) in 2015.
Dr. Morris has no relevant financial relationships to disclose.
-
Contains 10 Component(s)
To see the Learning Objectives and Outline for this section click the "View" button below.
Outline:
- Immune-related adverse events
- Radiation toxicities
- Endocrine therapy
- Bone health and management
After completing this educational activity, participants should be able to:- Describe appropriate management strategies for prevention and treatment of immune-related adverse events
- Identify and manage adverse events related to endocrine therapy
- Describe risk factors for bone toxicity and prescribe preventative and management strategies
Alison Morris
DNP, FNP-BC
Stanford Health Care
Alison Morris is a Hematology/Oncology Nurse Practitioner at Stanford Healthcare (SHC). Caring for cancer patients has been her passion since she was a nursing student. Alison began her career at UCLA in inpatient medical oncology in 2007 and later moved to Northern California. She has been working at Stanford Healthcare for the past 14 years. Alison worked as an inpatient Hematology/Oncology nurse, then as a Nurse Practitioner in inpatient Hematology/Oncology. She transitioned to outpatient Hematology/Oncology at Stanford Cancer Center- South Bay (CCSB), first as an Infusion Treatment Area APP and then transitioned to a mostly independent clinic practice caring for a spectrum of oncology and hematology patients. She is also the Lead APP at CCSB. She completed her Master’s in Nursing in 2013, and earned her Doctor of Nursing Practice (DNP) in 2015.
Dr. Morris has no relevant financial relationships to disclose.
This course was developed by the Advanced Practitioner Society for Hematology and Oncology (APSHO). Any recommendations contained in this course reflect APSHO's or Harborside's judgement regarding the state of general knowledge and practice in the field as of the date of publication. The recommendations may not be appropriate for use in all circumstances. APSHO and Harborside neither represent nor guarantee that the practices described herein will, if followed, ensure safe and effective patient care. Every healthcare provider should make their own determination regarding specific safe and appropriate patient care practices, including drug dosages and indications, considering patient specific characteristics, institutional policies and procedures, personnel, and equipment. The provider should always consult the most recent prescribing/product information. Though APSHO and the content creators have applied a rigorous review process to produce an error-free module, inadvertent mistakes can occur during the writing/editing/proofreading process. Information is not guaranteed to be accurate, complete, or current. APSHO, its editors, authors and reviewers cannot be held responsible for any liability incurred as a consequence for the application of any of the contents of this course contents. Figures and tables are used as examples and are not meant to be all-inclusive, nor do they represent endorsement of any particular therapy or institution. Websites mentioned are provided for information only and the website hosts are responsible for their own content and availability.
